Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Can't buy even 50 shares on AJB at the moment. Good news.
Name-checked on BBC News website article:
The first stage of the human challenge project will be delivered by a partnership between Imperial College London, the Royal Free Hospital's specialist and secure research unit in London and a company called hVIVO.
https://www.bbc.co.uk/news/health-54612293
[Apologies if already posted]
Order or no order, the Company has to decide whether to issue an RNS and the guidance from 'Key UK Listing Rule obligations' is reasonably clear but open to interpretation.
"Companies must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement. Issuers must also notify without delay information concerning a change in financial condition, performance or expectation of performance if the change would be likely to lead to a substantial share price movement."
Personally I prefer fewer rather than more, but striking a balance can be difficult I suppose. Some AIM companies seem to post when someone sneezes.
[Source: Thomson Reuters-Practical Law]
Any decision to invest at this moment (rather than in a week, or a month, or a year) must be based on upside potential versus downside risk.
It may not be of their own making, but the present situation is creating uncertainty amongst investors and you have to wonder what is driving this constant onslaught through the media.
Check out GErry's post below, explains some of the challenge.
Thanks for the posts today. I'm invested and see TSTL as a solid business with great prospects. Yet those with the most information keep on selling shares (and issuing more!) and that makes me too nervous - maybe I've misread this one.
At first I thought it was down to low salaries for directors but highest paid director's salary increased from £222k to £307k, 2018-2019: not huge, but certainly generous when one takes into account the HPD's Gain on Exercise of Options of £1.3m (2018: £340k).
It would be great to hear any counter-views on this point please.
Octopus is an interesting one; most recent investor info here:
https://media.octopusinvestments.com/m/4c08e6bcd0fdeafb/original/FP-Octopus-UK-Micro-Cap-Growth-factsheet.pdf
Midas share tip today
https://www.dailymail.co.uk/money/investing/article-8850329/MIDAS-SHARE-TIPS-UPDATE-EKF-help-Covid-fight.html
Parsley I agree and I'm not trying to second guess. As I said, there can be many reasons whyan employee sells.
To take your point about an employer giving me a note, I think more accurately it would be "here's shares options worth £300,000 now but a recent broker note suggests if you wait a while, they could be worth £7,000,000". I think I'd wait if I was full of confidence. But you're right, we don't know do we.
Happens often - there may be a number of reasons why someone sells all or part of a holding, but worth noting that here's one connected person who would rather take a couple of quid a share now than £10 or £40 or £50 later. I think!
As noted in ShaunP's analysis notes but mentioned specifically in response to Blackshepard's comments, for clarity.
Strange thing, or maybe not, Renalytix (RENX) is at the same address and has the same chairman, Christopher Mills, who has many directorships and an outstanding reputation.
Also at the same address and some overlapping directors in Verici DX, formed earlier this year.
Just for info!
Maybe not an issue (please feel free to critique) but Ekf don't appear to hold the patent for Primestore, rather they produce in the UK under contract. Longhorn own the patents and various global patents applied for. Have I got this wrong?
https://www.lhnvd.com/intellectual-property